Summary

Atrial fibrillation (AF) becomes more common with increasing age. Data from an unpublished new analysis of the Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation [ENGAGE AF-TIMI 48] support edoxaban as an alternative treatment to warfarin in elderly patients who require anticoagulation therapy. This article discusses a prespecified analysis that evaluated the association of age on study outcomes and the efficacy and safety of edoxaban relative to warfarin in the elderly with AF.